Introduction {#s1}
============

Heart failure (HF) is a compound clinical syndrome, comprising of a constellation of signs and symptoms portraying a reduction in cardiac output and/or increased in pressures in the heart chambers. Depending on left ventricular ejection fraction (LVEF), HF can be classified into HF with preserved ejection fraction (HFpEF), HF with mid-range ejection fraction (HFmrEF), and HF with reduced ejection fraction (HFrEF) \[[@R01]\]. There has been significant improvement in the treatment of cardiac diseases in the past few decades, but HF remains a serious public health issue because of its rising prevalence \[[@R02], [@R03]\] and poor prognosis \[[@R04]\]. It is well known that elevated heart rate (HR) is an independent risk factor for cardiovascular morbidity and mortality \[[@R05]-[@R07]\]. A high HR increases myocardial demand, decreases myocardial blood supply and oxygen (O~2~) delivery, shortens the diastolic filling time and increases cardiac filling pressures which consequently lead to a decrease in exercise capacity. In a recent study, an increase in LV diastolic pressure was observed in both patients with HFrEF and HFpEF \[[@R08]\]. Exercise intolerance in the form of dyspnea is one of the main symptoms of HF \[[@R01], [@R9]\], and it is of uttermost importance because it is related to poor quality of life (QOL) \[[@R10]\] and increased mortality. Currently there is no drug that has shown to have a significant effect on diastolic dysfunction or improved survival in diastolic HF. Therefore a therapeutic agent targeted at improving diastolic function and resultant increase in exercise tolerance in these patients is needed.

Ivabradine is a HR-lowering drug that selectively blocks the funny (I~f~) channels of the sinoatrial node thereby decreasing the pacemaker current. It is currently recommended in patients with HFrEF in sinus rhythm and a HR of ≥ 70 beats per minute (bpm) at rest despite optimum treatment with other standard therapy. Several studies have reported the effect of ivabradine on HR reduction, but not much is known about its effect on diastolic dysfunction and exercise tolerance. Some experiment studies however have demonstrated improvement of LV diastolic function and reduction in cardiac remodeling by I~f~ blockade \[[@R11], [@R12]\]. Accordingly, the aim of this meta-analysis is to investigate the effect of ivabradine on LV diastolic dysfunction, exercise capacity and QOL.

Materials and Methods {#s2}
=====================

This study was conducted in line with the preferred reporting items for systemic reviews and meta-analysis (Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)) \[[@R13]\].

Literature search and selection {#s2a}
-------------------------------

Two independent researchers (TRK and SKS) identified studies by searching the electronic databases of PubMed, EMBASE and Cochrane Central Register of Clinical Trials for studies on the effect of ivabradine on LV diastolic dysfunction, exercise tolerance, QOL of patients with HF (HFrEF and HFpEF).

Studies were included in this meta-analysis if they: 1) were randomized controlled trials (RCTs); 2) compared ivabradine treatment with standard medical care or other control group; 3) study population is adult (\> 18 years) with HF; 4) reported one or more of the following outcomes: LV diastolic dysfunction, exercise tolerance and QOL. The exclusion criteria were: 1) non-human studies; 2) articles in a language other than English; 3) abstract and posters.

Primary end points were LV diastolic dysfunction, exercise intolerance and QOL. Secondary endpoints considered were readmission for worsening HF and all-cause mortality. Echocardiographic measures of LV diastolic function which are early diastolic mitral inflow to late diastolic flow ratio (E/A) and early diastolic mitral inflow to annular velocity ratio (E/e') were extracted. The 6-min walk test (6MWT) and peak oxygen uptake during exercise (VO~2~) were extracted as measurement of exercise tolerance, and Minnesota Living with Heart Failure Questionnaire (MLHFQ) for QOL.

Data extraction and quality assessment {#s2b}
--------------------------------------

Data were systematically extracted from text, tables and figures from each study independently by two researchers (TRK and SKS), and tallied in an electronic database. These data included study name, author, year of publication, total number of patient studied and setting of the study, intervention, control, mean age, percentage of sex, mean HR, primary endpoints, clinical efficacy outcomes and duration of follow-up. Any disagreement was settled by discussion and consensus.

Statistical analysis {#s2c}
--------------------

We use STATA version 13 for statistical analysis. We calculate Cohen's d standardized mean difference (SMD), risk ratio (RR) for categorical events and 95% confidence interval (CI). The I^2^ statistic was used to describe the percentage variability that is due to heterogeneity. Heterogeneity in the eligible studies was evaluated using χ^2^ test on the basis of Cochrane's Q test and at P \< 0.10 level of significance. I^2^ values of 0-25%, 25-50% and \> 50% were considered to be low, moderate and high heterogeneity, respectively. When P for the heterogeneity is \< 0.1 and I^2^ ≥ 50%, the inter-study heterogeneity is considered significant. Publication biased was assessed graphically using funnel plot \[[@R14]\] and Egger meta-regression test to detect the potential source of heterogeneity.

Results {#s3}
=======

The literature search using key words yielded 881 articles. After removing duplicates and screening for relevancy, 75 articles were remained. Of these, 61 articles were excluded because they didn't meet the inclusion criteria. After a careful and thorough review, one study was excluded because the result was reported in median and not mean ± standard deviation (SD). A total of 13 RCTs met the criteria of inclusion in this study ([Fig. 1](#F1){ref-type="fig"}). Ten studies included patients with HFrEF, and four studies included patients with HFpEF.

![Flow diagram for studies included in the meta-analysis.](cr-11-040-g001){#F1}

Characteristics of the included studies on HFpEF are summarized in [Table 1](#T1){ref-type="table"} \[[@R15]-[@R17]\], and those on HFrEF in [Table 2](#T2){ref-type="table"} \[[@R18]-[@R27]\]. A total of 821 patients were enrolled in the 13 included RCTs with duration of follow-up ranging from 7 days to 6 months. There were 125 HFpEF in three studies and 696 HFrEF in 10 studies. The funnel plot of all studies demonstrates that there is low risk of publication bias ([Fig. 2](#F2){ref-type="fig"}). Eggers regression test shows that (coefficient: -4.091; 95% CI: -6.359485, -1.821423; P = 0.007). For the primary end point of interest in the HFpEF group, two studies reported on the effect of ivabradine on change in E/A, three on E/e' ratio, two on peak VO~2~, and one on 6MWT. In the HFrEF group, three studies reported on the effect of ivabradine on change in E/A, two on E/e' ratio, three on peak VO~2~, three on 6MWT and seven reported on QOL (MLHFQ score). For the secondary endpoints, three studies reported on hospital admission for worsening HF, and five studies over all reported on all-cause mortality.

###### Study Characteristics of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

  Author (year)                    Number of patients   Setting         Entry LVEF   Control   Mean age (yrs)   Men (%)   Mean HR at baseline (bpm)   Primary endpoint of interest   Follow-up
  -------------------------------- -------------------- --------------- ------------ --------- ---------------- --------- --------------------------- ------------------------------ -----------
  Kosmala et al, 2013 \[[@R15]\]   61                   Two centers     ≥ 50%        Placebo   67 ± 8           N/A                                   E/e', E/A, peak VO~2~          7 days
  Cocco et al, 2013 \[[@R16]\]     42                   Single-center   \> 50%       Digoxin   61.8 ± 4.4       48        85 ± 5                      E/e', E/A, 6MWT                3 months
  Pal et al, 2015 \[[@R17]\]       22                                   ≥ 50%        Placebo                    N/A       N/A                         E/e', peak VO~2~               2 weeks

LVEF: left ventricular ejection fraction; yrs: years; HR: heart rate; bpm: beats per minute; E/e': early diastolic mitral inflow to annular velocity ratio; E/A: early diastolic mitral inflow to late diastolic flow ratio; 6MWT: 6-min walk test; VO~2~: peak oxygen uptake during exercise; N/A: not available.

###### Study Characteristics of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)

  Author (year)                          Number of patients   Setting         Entry LVEF   Control            Mean age (yrs)   Men (%)   Mean HR at baseline (bpm)   Primary endpoint of interest   Follow-up
  -------------------------------------- -------------------- --------------- ------------ ------------------ ---------------- --------- --------------------------- ------------------------------ -----------
  Abdel-Salam et al, 2015 \[[@R18]\]     43                   Single-center   \< 40%       Placebo            50.8 ± 14.5      53.5      85 ± 12                     MLHFQ                          3 months
  Villacorta et al, 2018 \[[@R19]\]      19                                   \< 50%       Pyridostigmine                      N/A                                   Peak VO~2~, MLHFQ              6 months
  Mansour et al, 2011 \[[@R20]\]         53                   Single-center   \< 40%       Standard therapy   49 ± 113         60        N/A                         MLHFQ                          3 months
  Raja et al, 2018 \[[@R21]\]            125                  Single-center   \< 40%       Standard therapy   47.2 ± 15        56.9      94.9 ± 10                   6MWT, MLHFQ                    6 months
  Sarullo et al, 2010 \[[@R22]\]         60                   Single-center   \< 40%       Placebo            52.7 ± 5.3       75                                    Peak VO~2~                     3 months
  Sisakian et al, 2016 \[[@R23]\]        54                   Single-center   \< 40%       Standard therapy                    81        N/A                         E/A, E/e'                      3 months
  Volterrani et al, 2011 \[[@R24]\]      121                  Multicenter     HF           Carvedilol         66.8 ± 9.5       N/A       77.5 ± 12.2                 Peak VO~2~, 6MWT, MLHFQ        3 months
  Lofrano-Alves et al, 2016 \[[@R25]\]   26                                   \< 40%       Placebo                             N/A       N/A                         E/e', E/A                      6 months
  Fasullo et al, 2009 \[[@R26]\]         155                  Single-center   \< 50%       Beta-blocker                                                              E/A                            60 days
  Othman et al, 2019 \[[@R27]\]          40                   Single-center   \< 40%       Beta-blockers                                                             6MWT, MLHFQ                    1 month

LVEF: left ventricular ejection fraction; yrs: years; HR: heart rate; E/e': early diastolic mitral inflow to annular velocity ratio; E/A: early diastolic mitral inflow to late diastolic flow ratio; 6MWT: 6-min walk test; VO~2~: peak oxygen uptake during exercise; MLHFQ: Minnesota Living with Heart Failure Questionnaire; HF: heart failure; N/A: not available.

![Funnel plot of relative risk versus standard error.](cr-11-040-g002){#F2}

Effect of ivabradine on diastolic dysfunction {#s3a}
---------------------------------------------

As shown in [Figure 3a and b](#F3){ref-type="fig"}, in the HFpEF subgroup, there was significant reduction in E/A ratio (SMD: -0.53; 95% CI: -0.99, -0.07; P \< 0.000; I^2^ = 94.9%) in the ivabradine group compared to control. E/e' ratio was significantly increased in the control group (SMD: 0.95; 95% CI: 0.62, 1.27; P \< 0.000; I^2^ = 96.5%).

![Forest plot showing the effect of ivabradine on diastolic echocardiographic parameters compared with control in patients with HFpEF and HFrEF; change in E/A, and change in E/e'. E/e': early diastolic mitral inflow to annular velocity ratio; E/A: early diastolic mitral inflow to late diastolic flow ratio; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; CI: confidence interval.](cr-11-040-g003){#F3}

For the HFrEF subgroup, there was significant reduction in both E/A ratio (SMD: -0.33; 95% CI: -0.59, -0.06; P \< 0.000; I^2^ = 88.5%) and E/e' ratio (SMD: -1.01; 95% CI: -1.49, -0.54; P \< 0.012; I^2^ = 84.1%) in the ivabradine group compared to control ([Fig. 3c and d](#F3){ref-type="fig"}).

Effect of ivabradine on exercise tolerance and QOL {#s3b}
--------------------------------------------------

For the HFpEF subgroup, peak VO~2~ was significantly higher with ivabradine therapy than control (SMD: 0.05; 95% CI: -0.35, 0.45; P \< 0.00; I^2^ = 95.1%) ([Fig. 4a](#F4){ref-type="fig"}). For the HFrEF subgroup ([Fig. 4b and c](#F4){ref-type="fig"}), peak VO~2~ and 6MWT were significantly higher with ivabradine therapy than control (SMD: 0.83; 95% CI: 0.35, 1.32; P \< 0.00; I^2^ = 97.5%, and SMD: 1.11; 95% CI: 0.82, 1.41; P \< 0.000; I^2^ = 97.4%, respectively). MLHFQ score decreased significantly in the ivabradine group compared to control (SMD: -0.68; 95% CI: -0.91, -0.45; P \< 0.000; I^2^ = 97.5%) ([Fig. 5](#F5){ref-type="fig"}).

![Forest plot showing the effect of ivabradine on exercise tolerance (peak VO~2~ (mg/kg/min), distance on 6-min walking test (m)) compared with control in patients with HFpEF and HFrEF. VO~2~: peak oxygen uptake during exercise; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; CI: confidence interval.](cr-11-040-g004){#F4}

![Forest plot showing the effect of ivabradine on QOL (using MLHFQ score) compared with control. HFrEF: heart failure with reduced ejection fraction; CI: confidence interval; MLHFQ: Minnesota Living with Heart Failure Questionnaire; QOL: quality of life.](cr-11-040-g005){#F5}

Effect of ivabradine on worsening HF and all-cause mortality {#s3c}
------------------------------------------------------------

As shown in [Figure 6](#F6){ref-type="fig"}, there was no significant change in worsening HF and all-cause mortality in response to ivabradine therapy with RR of 1.44; 95% CI: 0.73, 2.16; P \< 0.148; I^2^ = 47.7% and RR of 0.76; 95% CI: 0.19, 1.33; P \< 0.907; I^2^ = 0.0%, respectively.

![Forest plot showing the effect of ivabradine on worsening heart failure and all-cause mortality. HFrEF: heart failure with reduced ejection fraction; CI: confidence interval.](cr-11-040-g006){#F6}

Discussion {#s4}
==========

For the heart to function as an effective pump, it has to be able to not only eject (systolic function) but also fill blood (diastolic function) \[[@R28]\]. Diastolic dysfunction is observed in both patients with HFpEF and HFrEF, and it is of clinical importance as it is closely related to symptoms of exercise intolerance and severity of HF \[[@R08]\]. The mainstay of treatment of HF is targeted at reducing the preload and afterload of the heart, and a lot of the big trials for HF management considered improvement in LV systolic parameters, whereas the optimal management for LV diastolic dysfunction is not well known. Ivabradine has been found to be beneficial in the management of HFrEF because of its HR-reducing effect. For example, in the recent multinational Systolic Heart Failure Treatment with the I~f~ inhibitor Ivabradine Trial (SHIFT) \[[@R29]\] in 6,505 patients with HF, ivabradine therapy was shown to have reduced the risk for the primary composite endpoint of cardiovascular death and readmission for worsening HF by 18%. While this was one of the backgrounds for including ivabradine to the guidelines for management of HFrEF, the SHIFT study did not assess the effect of HR reduction by ivabradine on change in diastolic dysfunction and symptoms of HF.

The result of our meta-analysis demonstrates that the use of ivabradine resulted in improvement in the primary outcome stated earlier. In the HFpEF group, there was a statistically significant improvement in diastolic function with decrease in E/A ratio, increase in exercise tolerance as seen in increase in peak VO~2~ with ivabradine therapy compared with control.

For the HFrEF group, with ivabradine therapy, there was significant improvement in diastolic function with decrease in E/A ratio and E/e' ratios, increase in exercise tolerance as seen in longer distance covered during 6MWT and an increase in peak VO~2~ compared with control. Also with ivabradine therapy there was an improvement in QOL evident by a reduction in MLHFQ score. However, there was no significant change in hospitalization for worsening HF and all-cause mortality when treated with ivabradine.

The major finding of this study was that ivabradine therapy improved diastolic function by decreasing LV filling pressures in both HFpEF and HFrEF. Cardiac output is a product of stroke volume and HR. In a patient with HF with an impaired stroke volume, there is a compensatory increase in HR to augment cardiac output. Therefore, by lowering HR with ivabradine, it allows the ventricles to have enough time to relax and fill, hence improving LV diastolic function \[[@R30]\]. Despite several studies demonstrating the effect of beta-blockers in HF, there are no large trials on its effect on diastolic dysfunction. One small retrospective study showed improvement of diastolic dysfunction with long-term beta-blocker therapy \[[@R31]\]. Nonetheless, there are no reports regarding the clinical benefit of this improved diastolic dysfunction. Also in addition to its negative chronotropic effect, beta-blockers also have a negative inotropic effect which is in contrast to ivabradine that purely reduces HR without affecting contractility of the cardiac muscles.

Our study also showed that ivabradine therapy improves exercise tolerance and QOL. Exercise intolerance is one of the hallmark symptoms of HF \[[@R10]\], and happens when augmented cardiac output is not sufficient enough to meet the metabolic demands imposed by exercise \[[@R32], [@R33]\]. During exercise, there is significant demand for oxygen in the metabolizing tissues. In healthy individuals, this demand is met by increasing both systolic and diastolic cardiac properties which combine to increase stroke volume, hence increase in cardiac output without a significant increase in diastolic pressure. However, in a failing heart, stroke volume during exercise increases with increase in LV end diastolic pressure because of diastolic dysfunction, resulting in exercise intolerance (dyspnea), and consequently reduced QOL \[[@R08]\]. Thus improving diastolic function with ivabradine therapy might be a contributing factor to the improvement seen in exercise intolerance.

In our meta-analysis, in contrast to the SHIFT trial, the use of ivabradine was not associated with significant change in readmission for worsening HF and all-cause mortality. Our findings however are consistent with a recent meta-analysis on the effect of ivabradine on patients with HFrEF by Hartmann et al \[[@R34]\], which showed that ivabradine significant decreased HR but had no effect on worsening HF or all-cause mortality. This can be explained by: 1) The studies included in our meta-analysis were relative smaller in comparison to the SHIFT study; and 2) The follow-up duration was shorter in our included study (ranges from 7 days to 6 months). So it will be inappropriate to report on long-term effect like all-cause mortality with relatively short follow-up.

While this study has its strengths, there are a few weaknesses to mention. Firstly, there were few RCTs that were eligible for inclusion in this study, and most of them had small population of patients. Secondly, even though the study consists of 13 RCTs, our primary outcomes of interest unfortunately were not consistently reported in all the studies. Therefore, larger RCTs are needed to validate results. Finally, there was high heterogeneity between the included studies because of population size and duration of follow-up. So to confirm the validity of the result of the present meta-analysis, we performed an Egger regression test.

To the best of our knowledge, this study is the first meta-analysis to demonstrate the effect of ivabradine on diastolic dysfunction, exercise tolerance and QOL.

In conclusion, ivabradine treatment has a positive effect on improving LV diastolic function by reducing E/A ratio in both patients with HFpEF and HFrEF, which is clinically relevant as it plays an integral role in the progression of HF \[[@R35]\]. This improvement translates to improvement of exercise tolerance and QOL. It however has a neutral effect on readmission for worsening HF and mortality.
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